Download our whitepaper,

"Understanding Attention-Deficit/Hyperactivity Disorder (ADHD): Epidemiology, Clinical Implications & Strategies for Clinical Trial Success"

ADHD

What's Inside:

  • Key FDA-Approved Pivotal Endpoints for ADHD Clinical Trials.
  • Optimizing Recruitment with Adaptive Trial Designs for ADHD.
  • Comprehensive Analysis of FDA-Approved ADHD Drugs.
  • How Diagnostic Criteria for ADHD Have Evolved and Impact Research.
  • Overcoming Common Pitfalls in ADHD Clinical Trials.
  • And additional insights to drive your trial's success.

Access your complimentary whitepaper today:

ADHD Clinical Trials

Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by persistent patterns of inattention, hyperactivity, and impulsivity that are more frequent and severe than typically observed in individuals at a comparable level of development.

The evolving understanding of ADHD has significantly impacted clinical practice and research directions. Clinicians now adopt a more integrated approach in diagnosis and treatment, considering the individual's life context, comorbid conditions, and unique symptom presentation. In research, there is an increasing focus on identifying endophenotypes, exploring non-pharmacological interventions, and understanding the long-term outcomes of those living with ADHD.


Roughly

55%

of children with ADHD continue to experience symptoms into adulthood

 



ADHD affects around

6%

of children worldwide

 

 

ADHD costs the U.S. economy roughly

$77b

each year due to healthcare expenses, work loss, and reduced productivity

 

Our clinical team has over

120

years of combined clinical trial experience